Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

NCT04791839 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Non-small Cell Carcinoma
Non-small Cell Lung Cancer

Interventions

DRUG: Zimberelimab
DRUG: Domvanalimab
DRUG: Etrumadenant

Sponsor

Washington University School of Medicine

Collaborators

[object Object]